Every year, 220,000 new cases of tuberculosis are registered in the Americas, and more than 50,000 die as a result of this disease. It is worth noting that tuberculosis is both preventable and curable, however it still is one of the most important transmitted infections in the world. Multiple factors explain this situation, one of them being the lack of commitment to treatment, due the amount of pills the patient must take and the side effects they may have. This raises the necessity of developing an efficient therapy that decreases negative side effects and permit proper adherence to the treatment. To this day there is no registered use of “Onnetsu” far infrared rays on patients suffering from tuberculosis. Take the case of a 67 year-old woman diagnosed with pulmonary tuberculosis (TB) based on clinical, radiological and bacteriological evidence, for which she was admitted in the National Health Strategy for the Prevention and Control of Tuberculosis (ESNPCT) and was receiving pharmacological treatment for 1 month (Rifampicin 300mg, Ethambutol 400mg, Isoniazid 100mg, Pyrazinamide 500mg), which she abandoned when she began having adverse reactions (nausea, vomiting, lose of appetite, weakness and dyspepsia). Due to this situation she went to the Traditional Medical Institute-IMET ESSALUD, where the diagnosis of pulmonary tuberculosis was confirmed and then signed and informed consent form where she agreed to receive “Onnetsu” far infrared ray treatment, which were applied to the skin, focussing on the thorax, done in one hour sessions, 3 times per week for 18 weeks, during which she received no pharmacological treatment. At the end of the treatment, betterment in both the clinical and radiological pictures and an adequate bacteriological response resulted in her being discharged from ESNPCT. Monitoring was done over the next 6 years y no evidence of active TB was found. This report could be the first step in opening the studies on the use of far infrared rays as a potential treatment for pulmonary tuberculosis.